This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
NOR-TEST was a completed phase 3 randomized double-blind parallel-group treatment trial evaluating tenecteplase versus alteplase for thrombolysis in acute ischemic stroke.
| Feature | NOR-TEST |
|---|---|
| Condition | Ischemic Stroke |
| Design | Randomized, parallel, double-blind |
| Primary purpose | Treatment |
| Enrollment | 1050 |
| Interventions | Tenecteplase versus alteplase |
| Status | Completed |
2. Clinical Question
Population
Patients with ischemic stroke.
Intervention
Tenecteplase thrombolysis.
Comparator
Alteplase thrombolysis.
Primary question
How do clinical functional outcomes compare between tenecteplase and alteplase at 90 days?
3. Trial Design
1050 patients
2 arms
90-day outcome
4. Endpoints
| Endpoint | Definition | Time frame |
|---|---|---|
| Clinical: Functional handicap | Excellent outcome defined as mRS 0-1 | 90 days |
5. Planned Analysis
The registry identifies the primary endpoint as a functional outcome measured using the modified Rankin Scale category of excellent outcome (mRS 0-1) at 90 days.
Functional outcomes measured on ordinal disability scales are commonly analysed using methods appropriate for categorical or ordinal outcomes, such as comparison of outcome distributions or regression models accounting for baseline factors when prespecified. The registry does not report posted statistical analyses or results for this endpoint on ClinicalTrials.gov.
6. Statistical Methodology
Randomization
Randomization creates comparable treatment groups on average and allows differences in outcomes to be interpreted within the framework of the assigned interventions.
Double-blind design
Double masking reduces the possibility that knowledge of treatment assignment influences outcome assessment or patient management.
Functional outcome analysis
The modified Rankin Scale is a disability outcome measure. The analysis approach must reflect the ordered nature of disability categories and the prespecified statistical plan.
7. Statistical Methods Explained
Why measure outcome at 90 days?
A 90-day assessment captures recovery after the acute stroke period and provides a standardized time point for comparing functional outcomes.
What does mRS 0-1 represent?
The registry defines excellent outcome as mRS 0-1, representing the endpoint category used for the primary outcome.
Why does randomization matter?
Random allocation reduces systematic differences between groups and supports unbiased comparison of assigned treatments.
Why is blinding important?
Blinding helps prevent expectations about treatment from influencing outcome assessment.
Why are categorical outcomes statistically challenging?
Disability outcomes contain ordered categories. Statistical methods should preserve information about that ordering rather than treating categories as unrelated binary events without justification.
8. Limitations
- The ClinicalTrials.gov record does not report posted statistical analyses or numerical outcome results.
- The registry does not report additional subgroup analyses, safety summaries, or detailed analysis populations.
- Interpretation of the primary endpoint depends on the prespecified statistical analysis plan.
9. Why This Trial Matters Statistically
| Concept | Application |
|---|---|
| Randomized trial design | Comparison of two thrombolytic interventions |
| Blinding | Reduction of assessment bias |
| Functional endpoints | Analysis of patient-centered outcomes |
| Time-to-assessment | Standardized 90-day evaluation |